BlossomHill Therapeutics, Inc. (BLSM) Stock Forecast
BLSM analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.80 / 5 from 5 analysts
- Price target
- $35.40 average of analyst targets
- Upside to target
- +153.9% from the latest close
- Next earnings
- —
- 52-week range
- $13.94 – $26.82
BLSM analyst ratings
5 analystsNumber of analysts at each rating.
BLSM price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BLSM earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.90 | −$0.92 | −$0.88 | — | — | 2 |
| Current fiscal year (2026) | −$5.09 | −$6.33 | −$3.86 | — | — | 2 |
| Next fiscal year (2027) | −$3.95 | −$4.14 | −$3.77 | −$5.09 | +22.4% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BLSM revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 5 |
| Current fiscal year (2026) | $0 | $0 | $0 | — | 5 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 5 |
BLSM EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BLSM EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | $0.00 | −$0.89 | −$0.90 | — | 0 up · 0 down |
| Current fiscal year (2026) | $0.00 | $0.00 | $0.00 | −$4.00 | −$5.09 | — | 0 up · 0 down |
| Next fiscal year (2027) | $0.00 | $0.00 | $0.00 | −$3.71 | −$3.95 | — | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BLSM earnings surprises
Reported EPS vs the consensus estimate for the last 1 quarters; BLSM beat in 0 of 1.
What analysts expect from BLSM
5 analysts cover BlossomHill Therapeutics; their consensus rating is strong buy (4.80 on a 1–5 scale, where 5 is a strong buy). The average price target is $35.40, 153.9% above the latest close of $13.94. Analysts expect earnings of −$5.09 per share for 2026. For 2027 the average estimate is −$3.95 per share. BlossomHill Therapeutics beat the EPS estimate in 0 of the last 1 quarters.
Related: BLSM income statement, BLSM key metrics, BLSM chart. See the BLSM stock overview for the latest quote and news.
BLSM forecast FAQ
What is BlossomHill Therapeutics's price target?
The average analyst price target for BlossomHill Therapeutics is $35.40, 153.9% above the latest close of $13.94.
Is BlossomHill Therapeutics a buy, hold or sell?
Of 5 analysts covering BlossomHill Therapeutics, 4 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is BlossomHill Therapeutics's EPS forecast?
Analysts forecast −$5.09 per share for 2026 (range −$6.33 to −$3.86); for 2027 the estimate is −$3.95.
Does BlossomHill Therapeutics usually beat earnings estimates?
BlossomHill Therapeutics reported EPS at or above the analyst estimate in 0 of the last 1 quarters.